Relevance of the prostate-specific antigen (PSA) nanotest compared to the classical PSA test in the organized mass screening of prostate cancer

被引:2
|
作者
Azzouzi, Abdel-Rahmene
Larre, Stephane
Cormier, Luc
Roupret, Morgan
Valeri, Antoine
Mangin, Philippe
Berthon, Philippe
Villette, Jean-Marie
Fiet, Jean
Cussenot, Olivier
机构
[1] CHU Angers, Dept Urol, F-49933 Angers, France
[2] CeRePP, UPRES, UFR, Biomed St Peres, Paris, France
[3] CHU Nancy Brabois, Dept Urol, Vandoeuvre Les Nancy, France
[4] CHU Cavale Blanche, Brest, France
[5] UroGene, Evry, France
[6] Hop St Louis, Dept Hormonol, Paris, France
[7] Inst Univ France, Paris, France
关键词
PSA; mass screening; prostate cancer; population surveillance;
D O I
10.1111/j.1464-410X.2006.06701.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE: To assess the reliability of a new measurement of prostate-specific antigen (PSA) using a blotting-paper assay (nanotest) compared to the standard PSA immunoassay. SUBJECTS AND METHODS: The PSA level was measured in 205 men volunteers (median age 70 years, range 41-75) using a nanotest and a standard PSA immunoassay, collected at the same time; 30 mu L of capillary blood placed on to a blotting paper were collected for the nanotest and sent by mail to the same laboratory for the two assays. The results were compared statistically using the Spearman test, the intraclass correlation coefficient and the Bland-Altman test. RESULTS: The nanotest threshold for an abnormal PSA level was 78 pg/mL, which corresponded to a standard PSA value of 3 ng/mL, with a sensitivity of 100%. There was a significant correlation (r = 0.98, Spearman test; P < 0.001) between the nanotest and the standard PSA assay. The intraclass correlation coefficient was 0.87. The Bland-Altman test showed a good agreement between the nanotest and the standard PSA assay, but there was an increasing proportional difference with increasing PSA value. CONCLUSION: There was a very high correlation between the nanotest and the standard PSA assay, especially for standard PSA levels of < 5 ng/mL. Economic and clinical studies are indicated to confirm the utility of the nanotest in organized mass screening of prostate cancer.
引用
收藏
页码:762 / 764
页数:3
相关论文
共 50 条
  • [41] Patient knowledge about prostate-specific antigen (PSA) and prostate cancer in Australia
    Pan, David
    McCahy, Philip
    BJU INTERNATIONAL, 2012, 109 : 52 - 56
  • [42] Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment
    Afshin Moradi
    Srilakshmi Srinivasan
    Judith Clements
    Jyotsna Batra
    Cancer and Metastasis Reviews, 2019, 38 : 333 - 346
  • [43] Free and complexed prostate-specific antigen (PSA) in the early detection of prostate cancer
    Tello, FL
    Prats, CH
    González, MDD
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2001, 39 (02) : 116 - 120
  • [44] Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications
    Gershman, Boris
    Van Houten, Holly K.
    Herrin, Jeph
    Moreira, Daniel M.
    Kim, Simon P.
    Shah, Nilay D.
    Karnes, R. Jeffrey
    EUROPEAN UROLOGY, 2017, 71 (01) : 55 - 65
  • [45] The use of prostate-specific antigen (PSA) for the monitoring of radiation therapy in prostate cancer
    Schafer, U
    Micke, O
    Hampel, G
    Brandt, B
    Bovenschulte, A
    Semjonow, A
    Willich, N
    ANTICANCER RESEARCH, 1997, 17 (4B) : 2983 - 2986
  • [46] Beyond the biomarker role: prostate-specific antigen (PSA) in the prostate cancer microenvironment
    Moradi, Afshin
    Srinivasan, Srilakshmi
    Clements, Judith
    Batra, Jyotsna
    CANCER AND METASTASIS REVIEWS, 2019, 38 (03) : 333 - 346
  • [47] Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands
    Shravana Kumar Jyoti
    Camille Blacke
    Pallavi Patil
    Vibha P. Amblihalli
    Amanda Nicholson
    Cancer Causes & Control, 2018, 29 : 87 - 92
  • [48] The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels
    Pelzer, AE
    Volgger, H
    Bektic, J
    Berger, AP
    Rehder, P
    Bartsch, G
    Horninger, W
    BJU INTERNATIONAL, 2005, 96 (07) : 995 - 998
  • [49] Algorithms based on prostate-specific antigen (PSA), free psa, digital rectal examination and prostate volume reduce false-postitive psa results in prostate cancer screening
    Finne, P
    Finne, R
    Bangma, C
    Hugosson, J
    Hakama, M
    Auvinen, A
    Stenman, UH
    INTERNATIONAL JOURNAL OF CANCER, 2004, 111 (02) : 310 - 315
  • [50] Prostate cancer screening by prostate-specific antigen (PSA); a relevant approach for the small population of the Cayman Islands
    Jyoti, Shravana Kumar
    Blacke, Camille
    Patil, Pallavi
    Amblihalli, Vibha P.
    Nicholson, Amanda
    CANCER CAUSES & CONTROL, 2018, 29 (01) : 87 - 92